

















Licensed products in pre-clinical & clinical phases

Reference	Indication/ Use	R+D	Pre-clinical	Phase I	Phase II	Phase III	Licensed	Research group
EYE-SCAFF project	LSCD syndrome							CB06/01/0003
Procedure for the procurement of solid micro- or nanoparticles	Administration of medicines							CB06/01/0033
Targeted delivery of therapeutic molecules to CXCR4 cells	Colorectal cancer							CB06/01/0014 CB06/01/1031
Nanostructured proteins	Cancer							CB06/01/0014 CB06/01/1031
Therapeutic nanoconjugates (1)	Cancer							CB06/01/0014 CB06/01/1031
Delivery of substances in senescent cells	Diseases where β -Gal is over-expressed							CB07/01/2012
Therapeutic nanoconjugates (2)	Cancer							CB06/01/0014 CB06/01/1031
Scaffold Proteins and Therapeutic Nanoconjugates	Cancer							CB06/01/0014 CB06/01/1031